Latest Interviews
Showing 1441–1455 of 2,593 transcripts.
Clear all filters- The Diary Of A CEO1h 31m
Michael Buble: "I Will NEVER Be Carefree Again!", Rejection, Cancer & Stealing!
Michael Bublé recounts a career defined by a decade of rejection and the strategic independence required to self-fund a demo that secured his Warner Bros. deal, ultimately achieving global success through his pivot to Southeast Asia. His trajectory shifted profoundly following his son Noah's cancer diagnosis, a crisis that dismantled his professional ego and reoriented his priorities toward faith, family, and a deliberate separation between his polished stage persona and his authentic personal identity. Currently, Bublé is leveraging his platform to explore acting, launch his Fraser & Thompson whiskey brand, and disrupt industry gatekeepers via social media, while maintaining a grounded perspective on wealth and legacy.
- Goldman Sachs33 min
Asset allocation outlook: The case for greater portfolio diversification in 2024
Christian Mueller-Glissmann, Alexandra Wilson-Elizondo, Alison Nathan
Goldman Sachs Research and Asset Management teams project a 2024 landscape defined by a strategic rotation out of underweight cash holdings toward a rebalanced 60-40 equity-bond mix to capitalize on normalizing inflation and renewed diversification benefits. While the U.S. economy is identified as late-cycle with a 30% recession probability, the firms recommend extending fixed income duration, utilizing equity put options for downside protection, and increasing exposure to private markets and real assets to navigate persistent structural inflation and AI-driven productivity divergence. This comprehensive strategy aims to achieve a soft landing by hedging against rising credit delinquencies and supply pressures while actively capturing alpha in a higher-rate environment where zero-interest rates are not expected to return.
- a16z1h 27m
Tony Robbins on the Future of Health & Longevity
Tony Robbins, Ben Horowitz, Marc Andreessen, Dr. Vijay Pande
Mark Cuban, Ben Horowitz, and Tony Robbins convened to examine the lag between medical innovation and clinical adoption, using Robbins' successful recovery from a severe neck and shoulder injury via unapproved stem cell therapy as a primary case study. The discussion highlighted how regulatory barriers, insurance dynamics, and academic stagnation currently hinder breakthrough treatments in fields ranging from precision medicine to mental health, while also addressing the societal need to shift from victimhood narratives toward personal autonomy. To bridge these gaps, the speakers outlined a vision where patients act as CEOs of their own health through data-driven diagnostics and retraining for a purpose-driven workforce, ultimately calling for a system that rewards outcomes over volume.
- Goldman Sachs28 min
Focus on financials: Why banks and asset managers are constructive about the economy in 2024
Richard Ramsden, Alex Blostein, Alison Nathan
Financial institutions now anticipate a soft landing with reduced recession risks, driven by stable deposit flows and a shift toward a higher-for-longer interest rate environment. While commercial lending stagnates due to tightened underwriting and regulatory capital requirements, the private credit sector is expanding rapidly as non-bank lenders absorb displaced loan demand. Concurrently, banks are fortifying reserves against commercial office real estate exposure and navigating a contentious regulatory framework that could further compress traditional intermediation while accelerating industry consolidation.
- a16z15 min
2024 Big Ideas: Anime Games Go Mainstream with Robin Guo
General Partner a16z's 2024 "Big Ideas" report identifies the expanding anime gaming ecosystem as a primary investment opportunity, citing *Genshin Impact* and *Honkai Impact 3rd* as benchmarks for cross-platform performance and revenue models exceeding industry averages. The analysis details how "gacha" monetization, evolving AI asset tools, and a shift from niche to mainstream demographics have lowered barriers for new entrants while driving billions in revenue. With studios like HoYoverse setting new standards for narrative depth and gameplay integration, the sector is poised for further growth in immersive XR experiences and AI-driven endless games.
- a16z24 min
2024 Big Ideas: AI-First Games That Never End with Jonathan Lai
A16Z partner Jonathan Lai forecasts a 2024 shift toward "AI-native" games that utilize Large Language Models to create dynamic, non-repeating narratives and lifelike companions rather than merely accelerating development. While current studios leverage AI for efficiency, new entrants are poised to disrupt the $200 billion market by pioneering subscription-based models designed to manage the variable costs of real-time generative processing. This evolution promises to reinvent core mechanics across genres, transforming static experiences into emergent worlds where players interact with adaptive agents.
- a16z15 min
Redefining Partnership with Adam Neumann
Adam Neumann, Ben Horowitz, Mark Andreessen, Elon Stern, Scott Writer, Caroline
Flow Living, founded by Adam and supported by a fully aligned financial partnership including a $350 million personal investment from Adam and Andreessen Horowitz, addresses the US housing supply gap by operating as a vertically integrated property manager, technology provider, and landlord. The company recently appointed CTO Scott Writer to lead technical strategy, leveraging his expertise in managing systems for billions of users to modernize a legacy real estate stack and implement dynamic pricing algorithms. Moving beyond traditional rent collection, Flow now controls 34% of a resident's income wallet through a unified app and is piloting an AI-driven community commerce model in Miami to drive retention and solve fragmentation in the market.
- a16z14 min
Big Ideas in 2024: Voice-First Apps Will Become Integral to Our Lives with Anish Acharya
A16Z partner Anish Acharya argues that advancements in large language models are transforming voice into a primary productivity interface by solving the historical "90% fidelity" problem that limited previous attempts. This shift enables new entrants to disrupt incumbents like Gmail through native voice-first workflows, moving human-computer interaction from simple commands to complex, passive conversations reminiscent of the film *Her*. While voice and graphical interfaces remain complementary, the technology is rapidly overcoming social and training barriers to redefine how executives and consumers manage digital tasks.
- a16z35 min
Launching a New Category with Modern Treasury's Dimitri Dadiomov
Dimitri Dadiomov, Seema Amble, Dmitry Dadimov
Launched in 2018 by Dmitry Dadimov, Sam Aaron, and Matt Marcus, Modern Treasury addresses complex payment reconciliation challenges by providing a unified platform that bridges developer APIs with financial dashboards. The company initially targeted early-stage startups with a "three-legged stool" architecture combining bank integrations and manual oversight tools before securing its first client through personal networks. By coining the "Payment Operations" category and prioritizing deep product mastery over competitive tracking, the founders established a defensible market position that evolved from manual reconciliation into a standardized infrastructure solution.
- Goldman Sachs20 min
M&A in 2024: Navigating opportunities and challenges
Stephan Feldgoise, Mark Sorrell, Allison Nathan
Following a 2023 period defined by valuation misalignments and high interest rates, the M&A market is experiencing a surge in dialogue and specific sector activity driven by resilient natural resources, healthcare, and stable industrial performance. While private equity deal volume has contracted due to financing costs, corporate buyers have maintained robust activity and public-to-private transactions have reached record levels to address pressure on portfolio monetization. Looking ahead to 2024, experts anticipate a normalization of interest rates and reduced inflation will catalyze a rebound in technology deals and strategic spinoffs, with international activity expected to trail the US market by several months.
- a16z25 min
Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde
Jorge Conde of a16z Bio + Health proposes "programming medicine" as a paradigm shift that reuses delivery platforms like SpaceX rockets to accelerate the development of genetic therapies beyond traditional bespoke drug cycles. This approach, validated by the recent FDA approval of a CRISPR-based sickle cell treatment achieved in just over a decade, aims to transform biological manufacturing through regulatory adaptability and engineering precision. Despite current hurdles regarding permanent safety, complex logistics, and multi-million dollar costs, the strategy seeks to apply exponential scaling to reduce treatment prices from millions to thousands of dollars for broader patient access.
- Dwarkesh Patel7 min
Will an AI smart enough to win math competitions be AGI? (Grant Sanderson @3blue1brown)
Two speakers debate the definition of Artificial General Intelligence, rejecting the idea of a discrete threshold and instead characterizing current models like GPT-4 as capable of applying a single algorithm across diverse tasks through continuous progression. While they anticipate that AI achieving a gold medal at the International Math Olympiad would represent a creative breakthrough in logical abstraction, they argue this milestone does not equate to general intelligence or significant economic disruption, as current systems still lack the context windows necessary for deep human intent analysis. Consequently, the discussion concludes that no single benchmark, including mathematical proficiency, serves as a definitive line for AGI, with current AI impact on job automation estimated to remain below one percent.
- Bank of America23 min
Lessons in Leadership: Holly O’Neill & Former Bank of America Vice Chair Anne Finucane
Former Bank of America Vice Chair Anne Finucane, who retired in late 2021 after pioneering the bank's sustainable finance strategies, now serves as Chair of Rubicon Carbon to advance rigorous carbon offset solutions alongside former EPA head Gina McCarthy. Her leadership journey, which spans local government, broadcasting, and global banking, emphasizes distilling complex issues and combining capitalism with scientific rigor to fund clean energy in emerging markets. Finucane applies this experience to advocate for social justice and climate action in 2024, leveraging her network to drive private capital toward global challenges while promoting humble, listening-based leadership.
- Dwarkesh Patel6 min
Where should society allocate mathematicians? (Grant Sanderson @3Blue1Brown)
The speaker challenges the academic funnel that directs mathematical talent exclusively into research, finance, or computer science by proposing NSF-mandated "forcing functions" that require non-mathematical collaboration. Citing Lars Doucet's pivot to Georgism-based startups as a proof of concept, the presentation advocates for collecting more narratives of mathematicians who apply abstract problem-solving to sectors like logistics and manufacturing. Ultimately, the argument concludes that high-impact career paths for gifted individuals should be determined by personal interests and specific societal needs rather than traditional institutional expectations.
- a16z24 min
Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo
Andreessen Horowitz partners project that democratizing miracle drugs like GLP-1s and cell therapies will define 2024, driven by a massive eligible U.S. population and the urgent need to prevent healthcare system insolvency. While these programmable medicines offer curative potential, their current exorbitant costs and complex logistics create severe friction in financing, manufacturing, and clinical operations. The industry is responding with 2024-focused innovations in industrialized biomanufacturing, fintech risk-spreading instruments, and real-world data infrastructure, all while awaiting necessary regulatory adaptations from the FDA and CMS.